Sanofi Pasteur, the vaccines division of Sanofi-Aventis has received a order from the US Department of Health and Human Services for an extra 27.3 million doses of the influenza A H1N1 (swine flu) 2009 virus vaccine.
The new order is for the production of bulk antigen equivalent to 27.3 million doses based on 15mcg of antigen per dose and will take the company’s total US vaccination order up to a total of 75.3 million doses of the pandemic vaccine.
Sanofi Pasteur president and chief executive Wayne Pisano said that as the only company manufacturing inactivated influenza vaccine in the US, Sanofi Pasteur is committed to responding to public health needs.
Sanofi Pasteur began commercial production of the new influenza vaccine in June using the novel monovalent virus strain to provide doses for clinical trials.
The company is testing the immunogenicity and safety vaccine in clinical trials, which began in the US on 6 August.
